Spots Global Cancer Trial Database for Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix

Official Title: Involvement of Matrix Metalloproteinases and Association With the Expression of Human Papillomavirus in Dysplasias and Cancers of the Cervix

Study ID: NCT04072913

Conditions

Papillomavirus Infections

Dysplasia

Cervix Cancer

Interventions

Vaginal samples (biopsies + vaginal smear)

Study Description

Brief Summary: This study aims to compare the expression of matrix metalloproteinases and their tissue inhibitors between 4 groups of patients defined according to the severity of the cervical lesion.

Detailed Description: Cervical cancer is the second most common cancer among European women under 45 years old. It is secondary to cervical dysplasia induced by persistent human papillomavirus infection. The involvement of matrix metalloproteinases in carcinogenesis of the cervix is real, but their expressions vary according to the published series. An association between the expression of MMPs and that of the human papillomavirus deserves to be explored, as this can have a prognostic influence in the case of gradual expression demonstrated in the development of (pre) cancerous lesions of the cervix. This study aims to compare the expression of matrix metalloproteinases and their tissue inhibitors between 4 groups of patients defined according to the severity of the cervical lesion.